Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Polyglandular autoimmune syndrome type II
ADR ID BADD_A10712
ADR Hierarchy
05      Endocrine disorders
05.09      Endocrine and glandular disorders NEC
05.09.02      Polyglandular endocrine disorders
05.09.02.002      Polyglandular autoimmune syndrome type II
10      Immune system disorders
10.04      Autoimmune disorders
10.04.08      Endocrine autoimmune disorders
10.04.08.002      Polyglandular autoimmune syndrome type II
Description Autoimmune diseases affecting multiple endocrine organs. Type I is characterized by childhood onset and chronic mucocutaneous candidiasis (CANDIDIASIS, CHRONIC MUCOCUTANEOUS), while type II exhibits any combination of adrenal insufficiency (ADDISON'S DISEASE), lymphocytic thyroiditis (THYROIDITIS, AUTOIMMUNE;), HYPOPARATHYROIDISM; and gonadal failure. In both types organ-specific ANTIBODIES against a variety of ENDOCRINE GLANDS have been detected. The type II syndrome differs from type I in that it is associated with HLA-A1 and B8 haplotypes, onset is usually in adulthood, and candidiasis is not present. [MeSH]
MedDRA Code 10036073
MeSH ID D016884
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Polyglandular autoimmune syndrome type II | Schmidt's syndrome | Autoimmune polyendocrine syndrome type II | Polyendocrinopathies, Autoimmune | Autoimmune Polyendocrinopathy | Polyendocrinopathy, Autoimmune | Polyglandular Type III Autoimmune Syndrome | Polyglandular Autoimmune Syndrome, Type 3 | Autoimmune Syndrome Type III, Polyglandular | Autoimmune Polyglandular Syndrome Type III | Autoimmune Polyglandular Syndrome, Type 3 | Polyglandular Type I Autoimmune Syndrome | APECED | APS Type 1 | Autoimmune Polyendocrinopathy Syndrome Type 1 | Autoimmune Polyendocrinopathy with Candidiasis and Ectodermal Dystrophy | Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy | Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy | Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy, Autoimmune | Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal-Dystrophy | Autoimmune Polyglandular Syndrome Type I | Autoimmune Polyglandular Syndrome, Type 1 | Autoimmune Polyglandular Syndrome, Type I | Autoimmune Syndrome Type I, Polyglandular | Polyendocrinopathy-Candidiasis-Ectodermal-Dystrophy, Autoimmune | Polyendocrinopathy Candidiasis Ectodermal Dystrophy, Autoimmune | Polyglandular Autoimmune Syndrome, Type 1 | Polyglandular Autoimmune Syndrome, Type I | AIRE Deficiency | AIRE Deficiencies | Deficiency, AIRE | Polyglandular Type II Autoimmune Syndrome | Autoimmune Polyendocrine Syndrome, Type II | Autoimmune Polyglandular Syndrome Type II | Autoimmune Syndrome Type II, Polyglandular | Diabetes Mellitus, Addison Disease, Myxedema | Schmidt's Syndrome | Syndrome, Schmidt's | Multiple Endocrine Deficiency Syndrome, Type 2 | Polyendocrine Autoimmune Syndrome, Type II | Polyglandular Autoimmune Syndrome, Type 2 | Polyglandular Deficiency Syndrome, Type 2 | Schmidt Syndrome | Syndrome, Schmidt | Autoimmune Polyendocrine Syndrome, Type 2 | Diabetes Mellitus, Addison's Disease, Myxedema
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01285Levothyroxine0.000007%
The 1th Page    1    Total 1 Pages